确定CLN3向蛋白质组表达特征的药物重定位候选者
Shixue Sun1, Rosemary Mejia1, An N Dang Do2
1Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, USA.
Proceedings. IEEE International Conference on Bioinformatics and Biomedicine
|September 17, 2025
概括
这项研究通过重新定位FDA批准的药物来确定青少年神经质脂 (CLN3) 的潜在新疗法. 伏利诺斯塔特和环素显示出治疗这种罕见的神经退行性疾病的前景.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 青春期神经质脂症 (CLN3) 是一种罕见的遗传性神经退行性疾病,没有有效的治疗方法.
- 缺乏治疗方法需要新的方法来治疗CLN3.
研究的目的:
- 开发一种用于CLN3治疗的药物重定向策略.
- 确定现有的FDA批准的药物,这些药物可能治疗CLN3.
主要方法:
- 从蛋白质组学数据构建了一个CLN3蛋白表达特征 (CPEP).
- 与CPEP查询iLINCS数据库,以找到具有逆转效果的药物.
- 根据监管强度,覆盖范围和血脑屏障透性优先考虑候选药物.
主要成果:
- 确定了60种FDA批准的药物,能够逆转CLN3 CPEP.
- 沃里诺斯塔特和环素因强烈的调节和血脑屏障透而成为最佳候选人.
- 该研究成功生成了潜在的CLN3治疗剂的优先清单.
结论:
- 药物重新定位为发现CLN3治疗提供了一个可行的策略.
- 伏利诺斯塔特和环素需要进一步研究作为潜在的CLN3疗法.
- 这种方法为开发针对CLN3的新型治疗干预措施提供了基础.
更多相关视频
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
1.6K
03:08Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
907
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...